BackPacific Biosciences of California Overview

Pacific Biosciences of California Total Current Liabilities

Latest total current liabilities for PACB: $33M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$33.49M
49.71% YoYΔ $-33.11M vs prior year quarter

Peer average

Loading

Pacific Biosciences of California Total Current Liabilities History

Loading

Pacific Biosciences of California vs. peers: Total Current Liabilities Comparison

Loading

Pacific Biosciences of California Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Pacific Biosciences of California (PACB) FAQ

Pacific Biosciences of California (PACB) currently reports a total current liabilities of $33M as of March 2026. That compares with $67M in the prior-year period — down 49.7% year over year. Use the charts on this page to explore Pacific Biosciences of California's total current liabilities history and peer comparisons.

Pacific Biosciences of California's total current liabilities decreased from $67M to $33M — a 49.7% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Pacific Biosciences of California reported $33M in total current liabilities as of March 2026. That compares with $67M in the prior-year period — down 49.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $33M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Pacific Biosciences of California, and consider following PACB for alerts when major investors trade the stock.

Pacific Biosciences of California is classified in the Healthcare sector. On total current liabilities, it currently shows $33M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PACB with unrelated industries.